Eloralintide vs Retatrutide: Mechanisms, Technical Profiles and Clinical Results

Eloralintide and retatrutide are investigational medicines being developed by Eli Lilly, but their technical approaches differ substantially. Eloralintide primarily mimics amylin-related satiety signals; retatrutide activates three receptors: GIP, GLP-1 and glucagon.

For a general reader, the key questions are how they affect the body, what clinical trials have actually found, and which adverse effects accompanied those results. As of October 26, 2026, both remain investigational. This article describes research findings and is not personal treatment advice.

Core technical differences

Parameter	Eloralintide	Retatrutide
Development code	LY3841136	LY3437943
Drug type	Selective amylin receptor agonist	GIP/GLP-1/glucagon triple receptor agonist
Mechanistic emphasis	Preferential AMY1 receptor activation; appetite and satiety regulation	Multiple pathways involved in appetite, glucose regulation and energy metabolism
Half-life in early human studies	Approximately 12.9–15.3 days in a single-dose study	Approximately 6 days
Administration in clinical trials	Once-weekly subcutaneous injection	Once-weekly subcutaneous injection
Representative monotherapy evidence	263 participants; 48-week Phase 2 trial	338 participants; 48-week Phase 2 trial, and 2,339 participants; 80-week Phase 3 trial
Development progress	Entered Phase 3 research	Results reported from multiple Phase 3 trials

Sources: Lilly’s eloralintide overview, eloralintide pharmacology study, retatrutide pharmacology study and TRIUMPH-1 publication.

How their mechanisms differ

Amylin is one of the hormones released after eating and helps communicate fullness to the brain. Eloralintide activates related receptors and is designed to preferentially activate AMY1. In everyday language, its approach is to strengthen signals associated with having eaten enough. It acts through a different receptor system from GLP-1 medicines. However, greater receptor selectivity does not automatically mean greater effectiveness or fewer side effects. Those questions require clinical evidence. Source: mechanism overview.

Retatrutide is a single molecule that activates three receptor types. GIP and GLP-1 participate in post-meal metabolic and glucose regulation, while GLP-1 signaling also contributes to appetite control. Adding glucagon receptor activity broadens the design to energy-metabolism pathways. It is not simply a mixture of three medicines, and “triple agonist” does not mean “three times the effect.” The balance between these pathways matters. Source: molecular design and early clinical research.

What the half-life difference means

Half-life is the time required for the blood concentration of a drug to fall by half. Early studies reported approximately 13–15 days for eloralintide and approximately 6 days for retatrutide. Under those study conditions, eloralintide was eliminated more slowly. This does not mean its clinical effect lasts twice as long, or that it can be taken every two weeks. Half-life, effect strength and dosing interval are different concepts. Both major clinical programs use weekly administration. Eloralintide study; retatrutide study.

What the 48-week trials found

Two separate Phase 2 trials enrolled adults with obesity or overweight without type 2 diabetes. Their shared 48-week duration makes the results informative to place alongside each other, but does not turn them into a direct comparison.

Trial feature	Eloralintide	Retatrutide
Total enrollment	263	338
Mean body-weight change in selected study groups	6 mg: −17.6%; 9 mg: −20.1%	Combined 8 mg groups: −22.8%; 12 mg: −24.2%
Placebo mean body-weight change	−0.4%	−2.1%
Publication	The Lancet	The New England Journal of Medicine

Doses identify trial groups and are not dosing instructions. Milligram amounts cannot be converted directly between these molecules. Sources: eloralintide Phase 2 trial and retatrutide Phase 2 trial.

Retatrutide’s higher-dose groups showed greater average weight reductions in these separate trials. That does not prove a 4.1-percentage-point advantage over eloralintide: participant characteristics, escalation schedules, placebo responses and statistical handling differed. A head-to-head trial would be needed to establish comparative efficacy.

What Phase 3 adds

Retatrutide also has larger and longer Phase 3 evidence. TRIUMPH-1 included 2,339 adults with obesity without diabetes over 80 weeks. Under the publication’s treatment-regimen estimand, average weight reductions were 17.6%, 23.7% and 25.0% for the 4 mg, 9 mg and 12 mg groups, versus 3.9% with placebo. Source: TRIUMPH-1 paper.

The widely reported 28.3% figure uses a different estimand from the 25.0% figure, with different handling of events such as treatment discontinuation. These numbers are not interchangeable. Trial duration, population and statistical approach matter alongside the headline percentage. Source: Lilly’s TRIUMPH-1 announcement.

Safety and tolerability

Observation	Eloralintide	Retatrutide
Common reported adverse effects	Gastrointestinal symptoms and fatigue, generally mild to moderate	Gastrointestinal symptoms, including nausea, diarrhea and vomiting
Relationship to study regimen	More frequent at higher doses; some reactions less frequent with slower escalation	Dose-related gastrointestinal effects in Phase 2
Other considerations	Larger studies are needed to refine risk assessment	Phase 2 showed dose-related heart-rate increases, peaking around week 24 and declining afterward

Good tolerability in some lower-dose eloralintide groups does not establish low risk at higher doses. Likewise, a heart-rate increase with retatrutide does not by itself establish an increase in cardiovascular events. Frequency, severity, discontinuation rates and long-term follow-up all matter. The available studies do not reliably establish which compound is safer. Sources: eloralintide Phase 2 announcement and retatrutide Phase 2 paper.

Eloralintide alone is not EloraTZP

EloraTZP combines eloralintide with tirzepatide. Its 2026 Phase 2b findings are combination-treatment evidence; they should not be attributed entirely to eloralintide alone and then compared with retatrutide. Source: EloraTZP Phase 2b results.

Retatrutide currently has more extensive Phase 3 evidence and has shown larger average weight reductions in the independent trials discussed. Eloralintide offers a distinct, selective amylin-based approach. Which is better suited to particular populations, better tolerated long term, or more durable after discontinuation remains unresolved by these comparisons. Different mechanisms and trial outcomes are established; a directly demonstrated winner is not.

Related product information

For additional product and technical information, see Eloralintide API product information and Retatrutide API product information.

Clinical findings cited in this article concern investigational trial formulations. They do not establish equivalent clinical validation of the products listed on this website. Product information is intended for qualified B2B partners only, not for personal use or direct consumer sale.